G 2/21: how to support inventive steps in patentability

Post-published evidence can be crucial to establishing patentability. G 2/21, the European Patent Office (EPO)’s referral to the Enlarged Board of Appeal (EBA) on the question of whether post-published evidence can be used to support the concept of “inventive step”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSPN Awards USA: Meet the judges

10 April 2026 The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.

Europe

UK patent office adopts EPO standards for AI inventions

9 April 2026 In light of Emotional Perception AI, the UKIPO has rewritten the rules for “mixed inventions". Matt Jefferies and Eric McNeil of Marks & Clerk explore what this pivot means for applicants protecting their AI technology.

Careers

Faegre Drinker boosts FDA regulatory practice with two senior hires

9 April 2026 The firm has added two partners to its government and regulatory team, bringing expertise in FDA matters, product approvals, and regulatory risk.

More features

UK patent office adopts EPO standards for AI inventions

Closing the women's health gap offers ‘benefits for all’

European patent offices raise fees

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

IndiaMart v CDSCO: A test of intermediary liability

EPO reports record patent filings, but pharma and biotech lag

HSF Kramer hires patent litigator as partner in Germany

Abbott IP chief: ‘Firms without AI policies scare me’

G 2/21: how to support inventive steps in patentability

More on this story

Editor's picks

Editor's picks

More features